BRNS vs HBAN · $38.2M cap vs P/E 13, rev $1.56B
Barinthus Biotherapeutics plc (BRNS) versus Huntington Bancshares Incorporated (HBAN) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
Huntington Bancshares Incorporated (HBAN) is a banks - regional company listed on US.
Latest reported BRNS revenue for 2025-09-30 was $0. Net income was -$14.6M. BRNS currently screens at market cap $38.2M.
Latest reported HBAN revenue for 2025-12-31 was $1.56B. Net income was $2.21B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
BRNS currently screens at market cap $38.2M. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
Not investment advice. Open the BRNS and HBAN stock pages for the full models.
Not investment advice.